We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cali Biosciences Co., Ltd., a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase 2b study of its perioperative long-acting analgesic product CPL- 01.